PD-L1 expression on the surface of tumor cells in advanced non-small cell lung cancer without driver gene mutations predicts the efficacy of anti-PD-1 therapy, thereby supporting PD-L1 as a biomarker to guide pembrolizumab-based therapy for this disease (28). The gene discussed is CD274; the disease is neoplasm.